Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
J Cell Physiol. 2019 Apr;234(4):5011-5022. doi: 10.1002/jcp.27302. Epub 2018 Nov 23.
Visfatin levels have been reported to be abnormal in many types of cancers. However, epidemiological studies yielded inconsistent results. Therefore, a meta-analysis was performed to assess the association between circulating visfatin levels and cancer risk. A systematic search was conducted for relevant studies in health-related electronic databases up to March 2018. Data related to standard mean difference (SMD) and overall odds ratio (ORS) were collected and analyzed. Summary SMD and pooled OR with 95% CIs were calculated using a random-effect model. Funnel plot and Egger's linear regression test were conducted to examine the risk of publication bias. A total of 27 studies with 2,693 cases and 3,040 healthy controls were included in meta-analysis for pooling SMD analysis. The results of the meta-analysis showed a significant higher visfatin levels in patients with various cancers than in controls, with a pooled SMD of 0.88, 95% CI = 0.56-1.20, p = 0.000. In subgroup, metaregression, Galbraith plot, and sensitivity analysis showed no substantial difference among all the analyzed factors. Data from 14 studies were also used for pooling ORs analysis. Metaresults revealed that high visfatin levels were associated with cancer risk (OR = 1.24, 95% CI: 1.14-1.34, p = 0.000). No evidence of publication bias was observed for pooling ORs and SMD analysis. This meta-analysis indicated a significant association between high circulating visfatin levels and increased risk of various cancers. Visfatin may represent a potential biomarker for early detection of cancers who may benefit from preventive treatment.Note.
内脏脂肪素水平在许多类型的癌症中都被报道为异常。然而，流行病学研究的结果并不一致。因此，进行了一项荟萃分析，以评估循环内脏脂肪素水平与癌症风险之间的关系。系统地检索了截至 2018 年 3 月与健康相关的电子数据库中的相关研究。收集并分析了与标准均数差（SMD）和总比值比（OR）相关的数据。使用随机效应模型计算汇总 SMD 和合并 OR 及其 95%置信区间。使用漏斗图和 Egger 线性回归检验来评估发表偏倚的风险。共纳入了 27 项研究，共 2693 例病例和 3040 例健康对照者，用于 SMD 分析的合并。荟萃分析的结果表明，各种癌症患者的内脏脂肪素水平明显高于对照组，合并 SMD 为 0.88，95%CI=0.56-1.20，p=0.000。在亚组、元回归、Galbraith 图和敏感性分析中，所有分析因素之间没有显著差异。还使用了 14 项研究的数据进行合并 OR 分析。荟萃结果表明，高水平的内脏脂肪素与癌症风险相关（OR=1.24，95%CI：1.14-1.34，p=0.000）。合并 OR 和 SMD 分析未发现发表偏倚的证据。这项荟萃分析表明，高水平的循环内脏脂肪素与各种癌症风险增加之间存在显著关联。内脏脂肪素可能代表了癌症早期检测的潜在生物标志物，这些患者可能受益于预防性治疗。注：
